Effects of a polypharmacy edit and reduced quantity limits on the utilization of triptans and overall costs in an integrated health system

Managed Care Interface

Volumn 19, Issue 5, 2006, Pages 46-51

  Dunn, Jeffrey D ^a   Cannon, H Eric ^a  

^a INTERMOUNTAIN HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN ANTAGONIST; TRIPTAN DERIVATIVE;

ARTICLE; DRUG COST; DRUG FORMULATION; DRUG UTILIZATION; EDUCATION; HEADACHE; HEALTH CARE; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HUMAN; MIGRAINE; POLYPHARMACY; PROPHYLAXIS; RISK MANAGEMENT;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DELIVERY OF HEALTH CARE, INTEGRATED; MANAGED CARE PROGRAMS; POLYPHARMACY; PRESCRIPTIONS, DRUG; TRYPTAMINES; UNITED STATES;

EID: 33745113530     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Stewart WF, Schecter A, Rasmussen BK: Migraine prevalence: A review of population-based studies. Neurology 1994;44(suppl 4):17-23.
2. Lipton RB, Stewart WF, Diamond S, et al: Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001;41:646-657.
3. Headache guidelines. American Headache Society (www. ahsnet.org/ guidelines.php), December 27, 2005.
4. Sumatriptan (prescribing information). Research Triangle Park, NC, GlaxoSmithKline, 2004.
5. Goadsby PJ, Lipton RB, Ferrari MD: Migraine-current understanding and treatment. N Engl J Med 2002;346:257-270.
6. Hoffman L, Mayzell G, Pedan A, et al: Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray. J Manag Care Pharm 2003;9:335-345.
7. Lassen DB, Boreen DM, Hyland-Marciniak BJ: Acute migraine therapy: Triptan quantity limit maintains total health care savings 1 year out. Formulary 2002;37:49-51.
8. Goldfarb SD, Duncan BS, Dans PE, et al: HMO direct costs and health care resources use after implementation of a monthly limit on sumatriptan. Am J Health-Syst Pharm 1999;56:2206-2210.